Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.60 |
| ▸ | PDE4A | P27815 | 5/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23047404 | 0.94 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL4278555 | 0.94 | PDE4B (0.63) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL28033753 | 0.94 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL30017688 | 0.90 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL21473561 | 0.90 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL28033773 | 0.89 | PDE4B (0.55) | PDE4BPDE4APDE4CPDE4DTSHR | |
| SCHEMBL20463312 | 0.87 | PDE4B (0.58) | PDE4BPDE4APDE4CPDE4DKMT2A | |
| SCHEMBL29670247 | 0.87 | TSHR (0.66) | PDE4BPDE4APDE4CPDE4DTSHR | |
| SCHEMBL15596058 | 0.87 | TSHR (0.66) | PDE4BPDE4APDE4CPDE4DTSHR | |
| SCHEMBL24815310 | 0.86 | MAPT (0.55) | PDE4BPDE4APDE4CPDE4DMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118067-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH SPA (IT) | 2013-05-08 | — | — | EP | disclosed |
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-20090264648-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
| WO-2009091832-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | PDE4B 353/4885PDE4A 287/4885PDE4C 324/4885 |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | PDE4B 437/4885PDE4A 388/4885PDE4C 431/4885 |
| US-20090264648-A1 | SYNTHESIS OF PYRAZOLES | CHRNA7, CHRNA5, CHRNA3 | PDE4B 326/4885PDE4A 382/4885PDE4C 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.